SOHO State of the Art Updates and Next Questions | Immunotherapeutic Options for Patients With Mantle Cell Lymphoma Who Progress on BTK Inhibitors

Clin Lymphoma Myeloma Leuk. 2023 Aug 14:S2152-2650(23)00258-6. doi: 10.1016/j.clml.2023.08.011. Online ahead of print.ABSTRACTMantle cell lymphoma is a challenging subtype of B-cell non-Hodgkin lymphoma treat characterized by its aggressive nature and propensity for relapse or refractory (R/R) disease for many patients. The introduction of Bruton's tyrosine kinase inhibitors has significantly improved the outcomes for patients with R/R MCL, but a considerable proportion of patients eventually experience disease progression or develop resistance to these agents. In recent years, immunotherapeutic approaches have emerged as promising treatment options. The treatment landscape is quickly progressing with the FDA approval of CAR-T cell therapy as well as several promising bispecific antibody therapies and antibody-drug conjugates in clinical development. This review article aims to provide a comprehensive overview of the current state of immunotherapeutic options available for patients with R/R MCL.PMID:37661513 | DOI:10.1016/j.clml.2023.08.011
Source: Clinical Lymphoma and Myeloma - Category: Cancer & Oncology Authors: Source Type: research